



**24<sup>th</sup> Annual Cancer Progress Conference**  
**March 5 & 6, 2013**  
**Conrad New York**

**AGENDA**

**Tuesday, March 5, 2013**

**7:00 – 8:00am Registration and Continental Breakfast**

**8:15 - 8:45am Opening Remarks**

Jeff Bockman, PhD, Vice President, Defined Health

**8:45 - 9:15am Keynote address**

Peter Bach, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center

**9:15 - 10:15am Translational Oncology: How Far Have We Come & Where Do We Need to Go Next?**

Moderator: Jeff Bockman, PhD, Vice President, Defined Health

Panelists:

- Chris H. Takimoto, MD, PhD, Vice President, Translational Medicine Early Development, Oncology Therapeutic Area, Janssen
- Greg Plowman, MD, PhD VP Oncology Research, Eli Lilly
- Pamela Carroll, PhD, Vice President, Oncology, Innovation Center, Janssen
- Kurt E. Bachman, PhD, Director, Molecular Medicines Unit, GlaxoSmithKline
- Dirk Jan Reitsma, MD, Vice President, Global Product Development Head, Oncology, PPD

**10:15 – 10:45am Networking Break**

**10:45 - 11:45pm    Changing AML Outcomes via Personalized Medicine:  
Transforming Cancer Management with Genetic Insight**

Co-Moderators:

- Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society &
- Mike Rice, Senior Consultant, Defined Health

Panelists:

- Brian J. Druker, MD, Director, OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Oregon Health & Science University, Investigator, Howard Hughes Medical Institute
- Eric Hedrick, MD, Chief Medical Officer, Epizyme, Inc.
- Omar Abdel-Wahab, MD, Assistant Member, Memorial Sloan Kettering Cancer Center
- Nicholas J. Sarlis, MD, PhD, Vice President & Head, Medical Affairs, Incyte Corporation
- Scott Biller, PhD, Chief Scientific Officer, Agios Pharmaceuticals

**11:45 - 12:45pm    Next Generation Diagnostic Approaches: From Arrays to  
Next Gen Sequencing – Will Data Points Lead Us to the  
Cure?**

Moderator:

- Colin Hill, Chief Executive Officer President & Chairman, GNS Healthcare

Panelists:

- Michael J. Pellini, MD, President & Chief Executive Officer, Foundation Medicine, Inc
- Donald Bergstrom, MD, PhD, Head of Translational Medicine, Oncology, Sanofi
- Brad Gray, President and Chief Executive Officer, NanoString

- Frank Diehl, PhD, Chief Scientific Officer and Managing Director, Inostics GmbH

**12:45 – 2:00pm      Networking Luncheon**

**2:00 - 3:00pm      The Challenges of Chemoprevention: How Can We Develop Drugs to Treat Cancer Risk Instead of Metastases?**

Moderator:

- Gary Kelloff, MD, Special Advisor, Division of Cancer Treatment and Diagnosis, National Cancer Institute

Panelists:

- Michael B. Sporn, MD, Professor of Pharmacology, Principal Investigator, Sporn Laboratory at Dartmouth Medical School
- Stephanie Blum-Sperisen, PhD, Head, Immunology, Nestlé Health Science SA
- William Nassib William, Jr, M. D. Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- V. Craig Jordan, PhD, Scientific Director, Lombardi Comprehensive Cancer Center at Georgetown University

**3:00 - 3:30pm      Networking Break**

**3:30 - 4:30pm      Growing a Cancer-Focused Biotech: Learning from Previous and Current Business Models**

Moderator:

- Sol J. Barer, PhD, Managing Partner, SJ Barer Consulting

Panelists:

- Michael Morrissey, PhD, President & Chief Executive Officer, Exelixis, Inc.
- James S.J. Manuso, PhD, Chairman & Chief Executive Officer, Astex Pharmaceuticals, Inc.

- Patrick J. Mahaffy, President & Chief Executive Officer, Clovis Oncology
- Mark Simon, Advisor, Torrey Partners LLC

**4:30- 5:30pm**

**Cancer Metabolism: Where Exactly is the Sweet Spot?**

Moderator:

- Marc Ruben, PhD, Associate Consultant, Defined Health

Panelists:

- Tak Mak, PhD, Director, The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute; University Professor, University of Toronto
- Matthew Vander Heiden, MD, Assistant Professor of Biology, MIT
- Charles Hart, PhD, Vice President of Biology, Threshold Pharmaceuticals

**5:30-8:30pm**

**Cancer Progress Reception**

---

**Wednesday, March 6, 2013**

**7:00 – 8:00am**

**Continental Breakfast**

**8:00 - 8:15am**

**Opening Remarks**

Mike Rice, Senior Consultant, Defined Health

**8:15 - 8:45am**

**Keynote Address**

Giulio Draetta, PhD, MD, Professor, Genomic Medicine Director, Institute for Applied Cancer Science, MD Anderson Cancer Center

**8:45 - 9:45am**

**Cancer Stem Cells: Getting Past the Controversies – Academic and Industry Perspectives on Key Targets & Development Paths**

Moderator:

- Jeremy Goldberg, President, JPG Healthcare LLC

Panelists:

- George Q. Daley, MD, PhD, Samuel E. Lux, IV Professor of Hematology, Director, Stem Cell Transplantation Program, HHMI/Children's Hospital Boston, Professor of Biological Chemistry/Molecular Pharmacology and of Pediatrics, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Manton Center for Orphan Disease Research
- Christoph Westphal, MD, PhD, Chairman & Chief Executive Officer, Verastem, Inc.
- Takashi Owa, PhD, Vice President & Chief Innovation Officer, Eisai
- Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics, Inc.

**9:45 - 10:15am      Networking Break**

**10:15 - 11:15am      Epigenetics – Are We There Yet? Building on the Foundations of DNMT and HDAC Inhibitors**

Panelists:

- Stephen B. Baylin, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Virginia & D.K. Ludwig Professor in Cancer Research, Associate Director of Cancer Center Research, The Johns Hopkins University, School of Medicine
- Keith E. Dionne, PhD, President and Chief Executive Officer, Constellation Pharmaceuticals
- Robert J. Gould, PhD, Chief Executive Officer, Epizyme, Inc.

**11:15 – 12:15pm      Pancreatic Cancer: Making the Intractable Tractable**

Moderator:

- Jordan D. Berlin, M.D. Professor of Medicine Ingram Professor of Cancer Research Clinical Director, GI

Oncology Program Director, Phase I Program,  
Vanderbilt-Ingram Cancer Center

Panelists:

- Margaret A. Tempero, MD, Director, UCSF Pancreas Center and Leader, Pancreas Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
- David Tuveson, MD, PhD, Professor and Deputy Director of Cancer Center Cold Spring Harbor Laboratory
- Charles J. Link, Jr. MD, Chairman, Chief Executive & Scientific Officer at NewLink Genetics Corp

**12:15 - 1:30pm      Networking Luncheon**

**1:30 - 2:30pm      Immunotherapy, Bringing It All Together: The Next Generation of Approaches & Combinations**

Moderator:

- Axel Hoos, MD, Vice President, Oncology Research and Development, GlaxoSmithKline

Panelists:

- Neil Berinstein, MD, Affiliate Scientist, Sunnybrook Research Institute
- Paul Higham, Chief Executive Officer, Immatics
- Sara Zaknoen, MD, CMO, Polynoma, LLC
- Dennis L. Panicali, Ph.D, Vice President, Technical Operations Bavarian Nordic ImmunoTherapeutics
- Charles J. Link, Jr. MD, Chairman, Chief Executive & Scientific Officer at NewLink Genetics Corp

**2:30 – 3:30pm:      Designing an Optimal Label for Commercial Success: When and How?**

Moderator:

- Jeff Bockman, PhD, Vice President, Defined Health

Panelists:

- Chandra Ramanathan, PhD, Head Early Pipeline Oncology Global Marketing SMBU, Bayer HealthCare Pharmaceuticals
- Usman Iqbal, MD, Senior Director and Head of Oncology, Sanofi
- Steve Heller, Global Marketing Leader, Oncology Strategy and Market Insight, Janssen, Pharmaceutical Companies of Johnson & Johnson

**3:30 – 4:00pm:      Networking Break**

**4:00- 5:00pm      Next Generation Biologics for Cancer Therapy: Beyond the Success of Conventional Monoclonal Antibodies**

Moderator:

- Mike Rice, Senior Consultant, Defined Health

Panelists:

- Christian Zahnd, PhD, Chief Executive Officer, Molecular Partners AG
- John Haurum, MD, Chief Executive Officer , F-Star
- Hans-Peter Gerber, PhD, Executive Director, Pfizer
- John M. Lambert, Ph.D, Executive Vice President & Chief Scientific Officer, ImmunoGen, Inc.
- Bill Grossman MD, PhD, Senior Vice President of Research & Development, Biothera

**5:00pm              Closing Remarks**

**5:15pm              Conference Concludes**